Table 3. Mean scores for the primary QoL outcome dimensions at 0, 9, 18 and 26 weeks by treatment group.
|
0 weeks
|
9 weeks
|
18 weeks
|
26 weeks
|
|||||
|---|---|---|---|---|---|---|---|---|
| C3 | C6 | C3 | C6 | C3 | C6 | C3 | C6 | |
| No. of patients alive | 150 | 147 | 129 | 127 | 96 | 99 | 75 | 80 |
| No. of questionnaires | 148 | 147 | 105 | 108 | 78 | 87 | 63 | 73 |
| Global QoL | 50.8 | 56.7 | 54.1 | 58.4 | 49.6 | 55.3 | 49.0 | 52.4 |
| Dyspnoea (QLQ-C30) | 49.0 | 48.3 | 46.1 | 41.7 | 53.0 | 47.7 | 54.5 | 46.6 |
| Dyspnoea (QLQ-LC13) | 37.9 | 37.8 | 38.6 | 35.0 | 45.1 | 37.6* | 47.9 | 38.3* |
| Pain | 35.7 | 30.6 | 30.6 | 27.8 | 29.5 | 30.7 | 34.7 | 38.8 |
| Fatigue | 47.2 | 44.5 | 49.8 | 47.1 | 49.4 | 50.2 | 52.1 | 51.1 |
QLQ=Quality of Life Questionnaire; QoL=quality of life.
All scale scores range from 0 to 100. For Global QoL, a higher score indicates better QoL, while for the symptom measures, a higher score indicates more pronounced symptoms.
*
P<0.05; Mann–Whitney U-test.